Biotechnology
Healthcare
Investing News
Market News
Technology
The Market Buzz
Adagio Therapeutics Reports ADG20 as First Monoclonal Antibody to Meet Primary Endpoints for Treatment of COVID-19
Adagio Therapeutics, Inc. (NASDAQ: ADGI) reports primary endpoints were met with statistical significance for all three indications of the company’s ongoing Phase 2/3 clinical trials evaluating its drug adintrevimab...